CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Recruiting now

Conditions studied: Breast Cancer

In brief

This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.

Key facts

Study ID

NCT05795335

Run by

RenJi Hospital

People needed

172

Starts

2023-04-30

Expected to finish

2028-12-30

Last updated by the study team

2023-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged ≥18 and older
• Confirmed diagnosis of hormone receptor-positive breast cancer.
• Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy.
• Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.
• ECOG 0-2
• Adequate organ function

You may not qualify if…

• Subjects disable to swallow pills.
• History of immunodeficiency disease

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.